CSIMarket Company Name, Ticker, Suppliers, else..
 
Theriva Biologics inc   (NYSE: TOVX)
 
Price: $0.2402 $0.01 4.435%
Day's High: $0.24130000174045563 Week Perf: -3.92 %
Day's Low: $ 0.23 30 Day Perf: 4.43 %
Volume (M): 334,077 52 Wk High: $ 0.86
Volume (M$): $ 0 52 Wk Avg: $0.26
Open: $0.24 52 Wk Low: $0.16



 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 46
 Employees 16
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Theriva Biologics Inc. is a biotechnology company that specializes in the development and production of therapeutic biological products. The company focuses on innovative approaches to treat various diseases, including cancer and autoimmune disorders. Their products are developed using advanced biologics technology and aim to improve patient outcomes and quality of life. Theriva Biologics Inc. is committed to research and development, clinical trials, and collaborations with partners to bring cutting-edge therapies to market.


   Company Address: 9605 Medical Center Drive, Suite 270 Rockville 20850
   Company Phone Number: 417-4364   Stock Exchange / Ticker: NYSE TOVX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CRMD   -3.27%    
GERN   -2.92%    
ISCO   -1.21%    
LGVN   -57.12%    
OMER   -1.99%    
SBFM   -17.58%    
• View Complete Report
   



Clinical Study

Theriva Biologics Navigating Financial Challenges Amidst Promising Clinical Developments

Published Tue, Oct 14 2025 8:33 AM UTC

Theriva Biologics Inc. has recently captured the attention of both the medical and financial communities. With anticipated presentations at high-profile medical meetings, particularly highlighting the VCN-01 expanded data from the VIRAGE Phase 2b trial to be presented at ESMO 2025, the company stands at a critical juncture in its clinical journey. However, alongside this pr...
Shares

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Published Wed, May 7 2025 1:18 PM UTC

Theriva Biologics: Innovating in Oncological Therapeutics with Strategic Offering Advancements and Positive Clinical Trial ResultsROCKVILLE, Md. May 07, 2025 Theriva Biologics (NYSE American: TOVX) is a company firmly on the radar of investors and the biotech community alike, thanks to its recent and strategic financial maneuvers alongside notable clinical trial advanceme...
Clinical Study

Theriva Biologics A Beacon of Hope in the Fight Against Cancer with Innovative Trials in Progress,

Published Thu, Oct 3 2024 12:00 PM UTC

Navigating New Frontiers: Theriva Biologics Advances Cancer Therapy Research with Promising Clinical Trials In the rapidly evolving landscape of oncology, clinical-stage companies are at the forefront of introducing innovative treatments aimed at addressing the pressing medical needs of patients suffering from cancer. One such entity making significant strides in this domain...
Stock Market Announcement

Theriva Biologics $2.5 Million Offering: Key Steps Toward Innovative Cancer Treatment Amid Market Challenges,

Published Fri, Sep 27 2024 1:07 AM UTC

Theriva Biologics Announces $2.5 Million Public Offering Amid Unprecedented Challenges in the Fight Against Metastatic Pancreatic CancerIn a strategic move indicative of both resilience and opportunity in the face of mounting challenges, Theriva Biologics, Inc. (NYSE American: TOVX) officially announced the pricing of a $2.5 million public offering. This offering, made publi...
Clinical Study

Emerging Synergies VCN-01 and Chemotherapy in the Fight Against Metastatic Pancreatic Cancer

Published Mon, Sep 23 2024 12:00 PM UTC

In a landscape where therapeutic advancements for metastatic pancreatic cancer remain critically needed, Theriva Biologics has made notable strides through its VIRAGE Phase 2b clinical trial. Targeting pancreatic ductal adenocarcinoma (PDAC), the trial investigates the combination of VCN-01, a viral-based therapy, with established chemotherapy regimens, including gemcitabine...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 36.74
Price to Sales (Expected) -
Price to Book 0.9
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.94
Working Capital Ratio 1.16
Leverage Ratio (MRQ) 1.86
Total Debt to Equity 0.14
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.86 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) 0.05 $
Cash 0.25 $
Book Value 0.27 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -820,500
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.